Bristol-Myers Squibb and Pfizer have announced a worldwide collaboration to develop and commercialize apixaban, an anticoagulant discovered by BMS being studied for the prevention and treatment of a broad range of venous and arterial thrombotic conditions. In a separate agreement, the companies will also collaborate on the R&D and commercialization of a Pfizer discovery program that includes advanced preclinical compounds with “potential applications for the treatment of metabolic diso...